↓ Skip to main content

Dove Medical Press

Article Metrics

Successful management of an inadvertent excessive treprostinil overdose

Overview of attention for article published in Drug Design, Development and Therapy, March 2013
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
29 Mendeley
Title
Successful management of an inadvertent excessive treprostinil overdose
Published in
Drug Design, Development and Therapy, March 2013
DOI 10.2147/dddt.s42771
Pubmed ID
Authors

Paul Zarogoulidis, Brachmann, Hornig, Friedel, Konstantinos Zarogoulidis, Wolfgang Hohenforst-Schmidt

Abstract

Pulmonary hypertension is defined by 25 mmHg pressure at rest, and 35 mmHg pressure at exercise, in the pulmonary arteries. Hypertension either primary or secondary. The exact prevalence of all types of pulmonary hypertension is not yet known. We present a case of a 58-year-old female patient suffering from CREST syndrome, Raynaud's syndrome, esophageal motility impairment, and severe pulmonary hypertension who had previously obtained a specially developed implantable pump, named Lenus Pro(®), to facilitate continuous parenteral treatment of pulmonary arterial hypertension with treprostinil. Treprostinil is a prostanoid derivative with very stable physiochemical properties which allows subcutaneous treatment of pulmonary arterial hypertension in the outpatient. Treprostinil is normally dosed individually in a range of 0.6 to 50 ng/kg/minute. In the underlying case, a dose of more than 100 mg given over 1 minute is equivalent to a 1000 fold overdose. The patient's critical condition required installment of a central venous access, full monitoring, sedation, oxygen nasal tube, fluid balance, and parenteral nutrition. The patient could be hemodynamically stabilized within 24 hours after the overdose. After 6 days of recovery, the patient left the hospital with no remaining health impairment.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 3%
Germany 1 3%
Unknown 27 93%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 24%
Student > Doctoral Student 5 17%
Librarian 4 14%
Student > Postgraduate 2 7%
Student > Ph. D. Student 2 7%
Other 5 17%
Unknown 4 14%
Readers by discipline Count As %
Medicine and Dentistry 14 48%
Pharmacology, Toxicology and Pharmaceutical Science 2 7%
Biochemistry, Genetics and Molecular Biology 2 7%
Nursing and Health Professions 2 7%
Social Sciences 2 7%
Other 5 17%
Unknown 2 7%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 May 2013.
All research outputs
#2,901,184
of 3,629,407 outputs
Outputs from Drug Design, Development and Therapy
#267
of 313 outputs
Outputs of similar age
#66,231
of 84,831 outputs
Outputs of similar age from Drug Design, Development and Therapy
#16
of 17 outputs
Altmetric has tracked 3,629,407 research outputs across all sources so far. This one is in the 2nd percentile – i.e., 2% of other outputs scored the same or lower than it.
So far Altmetric has tracked 313 research outputs from this source. They receive a mean Attention Score of 2.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 84,831 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.